Last reviewed · How we verify
Low Dose Clomiphencitrat
Low-dose clomiphene citrate acts as a selective estrogen receptor modulator (SERM) that blocks negative feedback on the hypothalamic-pituitary-gonadal axis, stimulating endogenous testosterone production in men.
Low-dose clomiphene citrate acts as a selective estrogen receptor modulator that blocks negative feedback on the hypothalamic-pituitary-gonadal axis, stimulating endogenous testosterone production in men. Used for Male hypogonadism with preservation of fertility, Testosterone deficiency in men.
At a glance
| Generic name | Low Dose Clomiphencitrat |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Selective estrogen receptor modulator (SERM) |
| Target | Estrogen receptor (ER-α and ER-β) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Clomiphene citrate competitively binds to estrogen receptors in the hypothalamus and pituitary gland, blocking the inhibitory effects of endogenous estrogen on gonadotropin-releasing hormone (GnRH) secretion. This disinhibition increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, which in turn stimulates testicular testosterone production. At low doses, this approach preserves testicular function and fertility while raising testosterone levels.
Approved indications
- Male hypogonadism with preserved or restored fertility
- Testosterone replacement therapy alternative in men desiring fertility
Common side effects
- Visual disturbances (blurred vision, scotomata)
- Hot flushes
- Mood changes
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Dose Clomiphencitrat CI brief — competitive landscape report
- Low Dose Clomiphencitrat updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI